Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AGMB 447

Next Previous
X
Search
Drug Profile

AGMB 447

Alternative Names: AGMB-447; ORG-447

Latest Information Update: 12 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Origo Biopharma
  • Developer AgomAb Therapeutics
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 06 Jun 2024 AGMB 447 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 14 Dec 2023 Phase-I clinical trials in Idiopathic pulmonary fibrosis in United Kingdom (Inhalation)
  • 01 Dec 2023 Agomab Therapeutics initiates a phase I trial for Idiopathic pulmonary fibrosis in the United Kingdom (NCT06181370)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top